

Toxicology in the 21st Century

# A New Tox21 Strategic Plan and the Integration of EPA Science

August 21, 2017

#### Rusty Thomas National Center for Computational Toxicology U.S. EPA

The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of any of the Federal agencies represented.














## Underlying Issues Facing Toxicology


Number of Chemicals /Combinations to Test




**Ethics Concerns** 




Human Relevance of Existing Tests



Lack of Data for Environmental Chemicals



Modified from Judson et al., EHP 2010





#### Formation and Renewal of U.S. Tox21 Federal Partnership

#### MEMORANDUM OF UNDERSTANDING

ON

High Throughput Screening, Toxicity Pathway Profiling, and Biological Interpretation of Findings



MOU Signed February, 2008; Revised July, 2010

APPROVAL XI.

National Toxicology Program

Linda S. Birnbaum, Ph.D., DABT, ATS

<u>5-11-15</u> Date

Director National Institute of Environmental Health Sciences National Institutes of Health

National Center for Advancing Translational Sciences

Christopher P. Austin, M.D.



Director National Center for Advancing Translational Sciences National Institutes of Health

U.S. Environmental Protection Agency

6/16/15

lek G Kadeli Acting Assistant Administrator Office of Research and Development U.S. Environmental Protection Agency

**U.S. Food and Drug Administration** 


June D. Mary Susan T. Mayne, Ph.D.

5/27/15 Date

Director Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration



## Toxicity Testing Data Generated by Tox21



\*Total number of assays is ~70



## Scientific, Public, and Regulatory Impact of Tox21

- Tox21 collaboration has published over 200 scientific peerreviewed articles in over 56 journals
- Top 5 Tox21 publications cited an average of over 100 times (Web of Science)
- Tox21 mentioned in over 70 news articles, 13 blogs, 461 Twitter posts, and 8 Wikipedia articles (AltMetric, Aug, 2017)
- Tox21 publications cited in over 140 policy-related and expert panel documents (AltMetric, Aug, 2017).
  - National Academies of Science Reports (~80)
  - Publications Office of the European Union (~15)
  - European Food Safety Authority (~5)
  - World Health Organization (~5)




#### But, the Focus of Tox21 has been Predominantly on HTS






#### Need to Expand Vision to Move Toxicity Testing into 21<sup>st</sup> Century






## The Challenge





## New Tox21 Strategic and Operational Plan




#### Areas of Focus

- 1. Develop and deploy alternative test systems that are predictive of human toxicity and dose response
- 2. Address key technical limitations of current *in vitro* test systems
- 3. Curate and characterize legacy *in vivo* toxicity studies to serve as a resource for interpreting Tox21 data
- 4. Develop framework for efficient validation of Tox21 approaches
- 5. Refine and deploy *in vitro* methods for characterizing pharmacokinetics to increase predictivity and reduce uncertainty



#### New Tox21 Structure





## Initial Infrastructure Teams and Example Cross Partner Projects

#### Infrastructure Teams

- Chemical Library Management
- Communications
- Assay Evaluation and Screening


#### Example Cross-Partner Projects


- In Vitro Disposition of Tox21 Chemicals
- Performance Based Validation of Tox21 Assays
- Development of a Reference Chemical Dataset for Interpretation of High-Throughput Transcriptomic Screening Data
- Incorporating Genetic
  Susceptibility into Developmental Neurotoxicity Screening



## Integration with EPA Science


#### **Common Components for Chemical Safety Decisions**







## **Integration with EPA Science**



#### Tox21 Projects with EPA Involvement

- Development of a High-Throughput Assay to Identify 5-α Reductase Inhibitors for Orthogonal Evaluation in an Androgendependent Human 3D Prostate Microtissue
- 2. Cell Line Selection for High-Throughput Transcriptomic Screening
- B. In Vitro Disposition of Tox21 Chemicals
- Development of a Reference Chemical Dataset for Interpretation of High-Throughput Transcriptomic Screening Data
- 5. Predictive Modeling of Developmental Toxicity with Human Pluripotent Stem Cells
- 6. Performance Based Validation of Tox21 Assays



## **Thank You for Your Attention!**

#### **EPA's National Center for Computational Toxicology**





National Center for Advancing Translational Sciences





National Institute of Environmental Health Sciences



#### National Center for Computational Toxicology